Roche announced today that the European Commission (EC) has granted conditional marketing approval for its bispecific antibody (bsAb) glofitamab, sold under the trade name Columvi, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The EC…

A phase I clinical trial at Stanford Medicine has found that a new CAR-T cell therapy that targets a different protein—CD22—from the original therapy significantly improved patients’ outcomes. Over half of 38 people enrolled in the trial—37 of whom had already relapsed from the original CAR-T therapy—experienced a complete response…

In a crucial Phase I/II trial, researchers at The University of Texas MD Anderson Cancer Center have reported significant success in treating patients with relapsed or refractory B-cell malignancies using cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19. The findings, published in Nature Medicine, show…

Researchers from Weill Cornell Medicine and New York-Presbyterian have identified a surprising mechanism that ultimately allows for DNA repair in cancer cells and in their both fundamental research and clinical studies have found a combination of chemotherapies that address these treatment-resistant lymphomas. Details of this approach, which is published in…

Lymphoma patients in a small, remote-based pilot project of dietary intervention for chronic fatigue mostly stuck with the diet, and the study results were promising. Lingering fatigue is one of the most significant effects after cancer treatment. There is evidence that diet changes can lift energy levels, but such research…

AbbVie and Genmab have announced topline results from the first cohort of the EPCORE phase 1/2 clinical trial of epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody they are co-developing. The study cohort includes 157 patients with relapsed/refractory large B-cell lymphoma (LBCL) who received at least two prior lines of systemic…

Research shows that presence of a mutated protein means that patients with activated B-cell diffuse large B-cell lymphomas will almost certainly develop resistance to a drug called ibrutinib, a targeted treatment for the cancer. The team, a collaboration between researchers at the University of Pennsylvania, Weill Cornell Medical College and…

A study from researchers at MD Anderson Cancer Center and Weill Cornell Medical School, published today in Cancer Discovery has demonstrated a new approach to treating two of the most common subtypes of lymphoma via manipulation of molecular programs controlled by the cAMP-response element binding protein (CREBBP). CREBBP mutations are…

Freenome’s multiomics platform, designed to improve early cancer detection from a routine blood draw, will be used by ADC Therapeutics to develop biomarkers for ADC’s pivotal-phase lymphoma drug candidate ADCT-402 (loncastuximab tesirine), through a collaboration whose value was not disclosed. The Freenome platform is designed to identify tumor- and immune-derived…

Scientists at Stanford University School of Medicine have just described in a new study how sequencing minute bits of DNA circulating in the blood of lymphoma patients can accurately identify the cancer subtype and pinpoint mutations that might cause drug resistance. The findings from this new study were published recently…

Researchers from the U.S. National Cancer Institute (NCI) have developed a chemotherapy-free, targeted treatment regimen that leads to durable remissions in people with certain types of diffuse large B-cell lymphoma (DLBCL). The five-drug ViPOR regimen, named for its inclusion of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, synergistically targets multiple molecular…

Researchers led by Didier Trono’s group at EPFL have uncovered a crucial survival tactic employed by cancer cells. The scientists identified a group of proteins, known as KRAB zinc finger proteins (KZFPs), that help cancer cells maintain genetic stability and avoid immune system detection. The team’s findings are published in…

Depending on which research report is referenced, there are anywhere from a couple hundred to more than 600 bispecific antibodies (bsAbs) in preclinical and clinical development by pharma and biotech companies around the world. Nine of the 12 bsAbs that have received approval globally target cancer. But after the first…

Precision medicine therapy developer Denovo Biopharma LLC, announced dosing of the first patient in its biomarker guided Phase III clinical study evaluating the enzastaurin (DB102) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma multiforme (GBM). The randomized, double-blind, placebo-controlled global study is plans to…

Scientists led by teams at Dana-Farber Cancer Institute and Mass General Cancer Center have created molecular ON-OFF switches that can regulate the activity of chimeric antigen receptor (CAR) T cells, a form of cell-based immunotherapy that has demonstrated dramatic success in treating some advanced cancers, but which poses a significant…